Targeting Amylin for Developing Anti-Obesity Therapeutics
InquiryOverview
Amylin is a satiety hormone that is secreted into the bloodstream by pancreatic cells. It transmits signals to areas such as the hypothalamic nuclei, initiating postprandial anorexia signaling which suppresses appetite and reduces food intake. In addition, amylin acts as an inhibitory signal, suppressing glucagon secretion and slowing gastric emptying. It has been found that long-term administration of amylin in rats resulted in weight loss and reduced fat deposition. Therefore amylin analogs are potential anti-obesity drugs for the treatment of obesity or overweight. Some amylin analogs have been developed to promote better glycemic control and weight loss. Protheragen offers a comprehensive amylin-targeting anti-obesity therapeutic development service. We are pioneers in anti-obesity therapeutic development services, facilitating anti-obesity research and therapeutic innovation through comprehensive experimental protocols.
Exploring Innovative Anti-Obesity Therapies at Protheragen
Our team combines scientists with extensive experience in molecular biology, biopharmaceutical engineering, and other areas to support clients at every stage of amylin-targeted anti-obesity therapy development. Specific services include the following:
Anti-Obesity Drug Development
Amylin has been identified as a potential target for the treatment of obesity. Based on the latest advances in amylin research, we develop more efficient anti-obesity drugs to reverse obesity and evaluate their therapeutic potential. In addition, we search for the most suitable delivery system for anti-obesity drugs to increase the effect and minimize adverse effects.
- Computer-aided drug design: We use computer simulations to predict the binding affinity between potential anti-obesity drugs and receptors, which is a basis for designing and optimizing lead compounds. This process includes steps such as molecular docking, molecular dynamics simulation, and new drug design.
- Amylin analogs: We synthesize various amylin analogs and evaluate their efficacy, potency, and safety in the treatment of obesity. Natural amylin has a short half-life and limited efficacy in treating obesity. We extend the half-life of amylin analogs by coupling the peptide chain to a molecular scaffold such as polyethylene glycol or modifying the peptide chain by glycosylation, increasing their efficacy in treating obesity and reducing the frequency of administration.
- Amylin and Leptin: Studies have found that the combination of amylin and leptin produced a more effective treatment of obesity. We co-administer amylin or amylin analogs with leptin and analyze food intake, body weight changes, body fat changes, etc., in treated animal models.
- Dual amylin and calcitonin receptor agonists: Amylin receptors are activated by the interaction of amylin and other hormones with similar structures (calcitonin, calcitonin gene-related peptide, etc.). Of these, calcitonin has been shown to activate several amylin receptor subtypes. At the same time, amylin has an affinity for both amylin receptors and calcitonin. The use of dual amylin and calcitonin receptor agonists has been found to reduce fat deposition in liver tissue, improve glucose tolerance, and significantly reduce body weight. We design and evaluate the therapeutic potential of dual amylin and calcitonin receptor agonists for the treatment of obesity.
- Other strategies: We also combine amylin with several other compounds with anti-obesity capacity to produce beneficial therapeutic effects.
Preclinical Studies of Anti-Obesity Therapies
Our preclinical research services consist of three components: model construction, assessment of drug therapeutic efficacy, and safety evaluation. Combined with a variety of cutting-edge technologies, we provide rapid project turnaround and high-quality assay data to accelerate research on a variety of anti-obesity drugs.
- Obesity Models: We have constructed a variety of obesity models, including diet-induced models, Gene Editing Models, etc. These models play a crucial role in understanding the anti-obesity potential and drug interactions, analyzing the molecular mechanisms of obesity, and assessing toxicological properties. In addition, we also provide customized obesity models to best meet our clients' experimental needs.
- Evaluation of anti-obesity therapies: Pharmacological, pharmacokinetic, safety, and other biological analyses are performed. Our well-trained research team has extensive experience in preclinical studies and responds quickly to our clients' analytical testing needs, providing reliable service and professional support.
Workflow
We keep abreast of research advances in innovative anti-obesity therapies and provide support at every experimental stage of therapy design, obesity modeling, and preclinical studies.
Applications
- Combination therapies: Amylin analogs may provide better weight loss in combination with other compounds than monotherapy.
- Metabolic diseases: Amylin analogs are also potential potential drugs for the treatment of metabolic diseases.
- Diabetes: Amylin analogs are used to optimize diabetes therapies based on their role in glucose homeostasis, etc.
Advantages
- Our experienced research team understands the uniqueness of each research project, provides an in-depth understanding of the client's needs, and offers customized development of anti-obesity therapies targeting amylin.
- We use multiple strategies to modify amylin to synthesize anti-obesity drugs with longer half-lives and better therapeutic efficacy.
- We use a variety of advanced tools to comprehensively evaluate the anti-obesity effects of amylin analogs, providing strong support for our client's research.
Leading-edge Services for Obesity Research
Protheragen is a leader in obesity research and the development of anti-obesity therapies, translating extensive experience into effective solutions. We offer comprehensive obesity analysis services that explore the impact of genetic, environmental, and metabolic factors on obesity. Advanced diagnostic methods help assess the progress of obesity interventions, while predictive services utilize algorithms and genetics to predict the risk of developing obesity. We also test for individual obesity biomarkers, offer obesity-related gene-editing services, and study differences in microbiomes and pathologies across samples to advance obesity research. We also provide weight loss and weight management services to ensure that scientific monitoring promotes weight loss.
Publication
Technology: Chemical modification
Journal: Frontiers in Endocrinology
IF: 6.055
Published: 2021
Results: This article summarises the pathology and physiology of amylin and calcitonin in obesity, among others, and delves into the potential therapeutic role of both substances in obesity and other metabolic diseases. Amylin interacts with calcitonin and modulates amylin receptors. Several drug therapies based on amylin and calcitonin have been developed, such as long-acting pancreatic amyloid peptide agonists and salmon calcitonin. Long-acting islet amyloid peptide analogs have been shown to reduce energy intake and body weight in rats and have good developmental value. Salmon calcitonin has been shown to have longer receptor activation and binding times. This paper provides theoretical support for the design of anti-obesity drugs targeting amylin.
Fig.1 Theoretical physiological role of amylin and calcitonin receptor activation. (Mathiesen, et al., 2021)
Frequently Asked Questions
What is the role of computer-aided drug design in anti-obesity drug development?
- Binding mode prediction: The interactions between amylin analogs and receptors are studied or predicted, and their binding affinities are analyzed to facilitate compound design and optimization.
- High-throughput virtual screening: We rapidly find amylin analogs from compound libraries that bind to receptors, shortening experimental cycles and increasing hit rates.
What other anti-obesity therapeutic development services targeting hormones and peptides do we offer?
- Anti-obesity therapy development targeting Leptin
- Anti-Obesity Therapy Development Targeting Adiponectin
- Anti-Obesity Therapy Development Targeting Ghrelin
- Anti-Obesity Therapy Development Targeting Exendin
- Anti-Obesity Therapy Development Targeting Fibroblast Growth Factor (FGF)
- Anti-Obesity Therapy Development Targeting Interleukin
- Anti-Obesity Therapy Development Targeting Glucagon-Like Peptide 1 (GLP-1)
Protheragen keeps abreast of advances in obesity research and is committed to the development of effective, safe, and efficient obesity treatment strategies targeting amylin. Our team is always eager to serve our clients. Welcome to contact us to discuss the details of the anti-obesity therapy research.
Reference
- Mathiesen, D.S.; et al. Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat. Frontiers in Endocrinology. 2021, 11: 617400.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.